Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common arthritis drug tame recurring eye inflammation?

NCT ID NCT03020992

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether certolizumab pegol (Cimzia), a drug already used for arthritis, can reduce flares of anterior uveitis—a painful eye inflammation—in people with axial spondyloarthritis who have had uveitis before. About 89 adults with active axial spondyloarthritis and a history of uveitis will receive the drug and be monitored for new eye inflammation episodes over 48 weeks. The goal is to see if the drug can prevent or reduce these flares.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
certolizumab pegol (Cimzia)
What this could lead to
If it works, this could offer a way to reduce painful eye inflammation flares in people with axial spondyloarthritis.
What could go wrong
This is a small, open-label study without a placebo group, so results may be less reliable. The drug may not work for everyone and carries risks like infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTERIOR UVEITIS (AU) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anterior uveitis Axial Spondyloarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTERIOR UVEITIS (AU) AXIAL SPONDYLOARTHRITIS (AXSPA)

Contacts and locations

Locations

  • As0007 101

    Brno, Czechia

  • As0007 102

    Prague, Czechia

  • As0007 103

    Brno, Czechia

  • As0007 105

    Prague, Czechia

  • As0007 107

    Brno, Czechia

  • As0007 108

    Ostrava, Czechia

  • As0007 109

    Pardubice, Czechia

  • As0007 301

    Freiburg im Breisgau, Germany

  • As0007 302

    München, Germany

  • As0007 303

    Münster, Germany

  • As0007 401

    Amsterdam, Netherlands

  • As0007 501

    Warsaw, Poland

  • As0007 502

    Torun, Poland

  • As0007 504

    Wroclaw, Poland

  • As0007 505

    Warsaw, Poland

  • As0007 506

    Bialystok, Poland

  • As0007 507

    Wroclaw, Poland

  • As0007 508

    Wroclaw, Poland

  • As0007 509

    Poznan, Poland

  • As0007 510

    Lublin, Poland

  • As0007 511

    Poznan, Poland

  • As0007 601

    Córdoba, Spain

  • As0007 604

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.